We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Intl.Brand | IBL | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 16.00 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 16.00 | 16.00 |
| Top Posts |
|---|
Posted at 07/7/2010 08:11 by robward Morning AllIBL have now been de-listed and the epic to use is EKF. Regards Rob |
Posted at 28/5/2010 07:41 by wan Just a reminder given timeframes were mentioned -26 November 2009 Board Changes, New Strategy, Disposal and Placing Under the AIM Rules for Companies, shareholders' approval is required for the change of strategy and it is proposed to post a circular to shareholders shortly; seeking such approval at a general meeting. Once approved by Shareholders the Company will have 12 months to make an acquisition, or acquisitions, which constitute a reverse acquisition or implement its investing strategy. The Board anticipates it will make an acquisition which will constitute a reverse acquisition within this time frame. 4 January 2010 Result of General Meeting International Brand Licensing plc (the "Company") is pleased to announce that at the General Meeting held earlier today all resolutions were approved by shareholders. |
Posted at 28/4/2010 10:19 by stirfry13 Another article with quotes from Julian Baines, this from one from March about using AIM:Investors have become extremely choosy about the sectors they will back. Healthcare is a firm favourite, on the basis that people are always willing to spend on keeping fit and healthy. The right technology and energy companies may get a look in too. One Welsh entrepreneur among the handful to get access to AIM recently is Julian Baines. He and colleague David Evans acquired AIM-listed cash shell International Brand Licensing in January to develop a health diagnostics business. Their track record includes British Biocell International, which they sold in 2008. "BBI had high profits and good growth potential, and so will the companies we're looking to acquire," says Baines. He's aware of risk aversion across the whole stock market but is not deterred. "I think it's a solid, positive change. Now isn't a bad time at all to come back to the market if you have solid businesses with good growth and a high reputation." Funding growth through acquisitions which is IBL's strategy is where AIM is particularly supportive compared with private equity. BBI made seven acquisitions in the three-and-a-half years after it floated, compared with none in the four years it was under venture capital ownership. Baines already has three acquisition targets in his sights. Once the first is complete he will give IBL a more appropriate name and set up a corporate headquarters in Cardiff. Listing on AIM, he says, "really is an easier way of rapidly growing a business if you're starting from a very strong base" |
Posted at 19/4/2010 16:52 by stirfry13 no point buying IBL only to then buy another plc (vdn).all gone very quiet here; seems to be taking longer than the press article made it sound. |
Posted at 15/4/2010 09:08 by piedro What are the chances of IBL being interested Vindon Healthcare, VDN ?One director has defected Zeus Capital holds 34% It is profitable and relatively cheap with bluechip clients though not exactly diagnostic. |
Posted at 11/2/2010 13:17 by silverfern well how would we know!! :) As I posted previously, whatever the deal being done, it was being done before Evans and co joined the board. They found IBL not vice versa - they were looking for a shell to back into and this was a pretty good one (given it had assets still to sell to keep it 'trading') |
Posted at 05/1/2010 17:51 by stirfry13 the money put into the business by the new board can't have been an arbitrary amount - there must have been something close to an agreed price for the takeover target plus an idea of what's needed for initial working cap and even some development costs before buying into IBL imho |
Posted at 05/1/2010 11:48 by stirfry13 Good news. More cash in the pot with today's RNS:INTERNATIONAL BRAND LICENSING PLC SELLS STAKE IN ADMIRAL ASIA ("IBL" or "the Company") International Brand Licensing Plc (AIM: IBL) announces that it has sold its 49% stake in the joint venture company, Admiral Asia Limited ("AAL"), to its existing partner, Rich Crest Group, for a cash consideration of £375,000. Included in the transaction are the Admiral trademarks for the Russian Federation. Julian Baines, IBL's CEO, comments: "We are delighted to have completed this disposal following the recent announcement of the Company's new strategy to withdraw from the sporting goods industry and move into the in vitro diagnostics devices ("IVD") market place." IBL will continue to sell off the remainder of the its worldwide sports IP assets, which will generate additional cash to invest in the Company's IVD growth. |
Posted at 16/12/2009 09:09 by stirfry13 bought these about 10 years ago before company split to create ibl and had written them off as worthless, but i'm interested again now, a ten bagger and i'll get my money back! but i've topped up now with a decent amount and i'm up for the ride. here's to the 'all new' ibl. |
Posted at 26/11/2009 08:07 by philjeans International Brand Licensing plc ("IBL" or "the Company") Board Changes, Proposed New Strategy, Disposal of Existing Business and Placing Key points The Board of IBL is pleased to announce: * New Board appointments with David Evans joining the Board as non-executive chairman, Julian Baines as CEO and Dr Kevin Wilson as non-executive director. * Proposed change in the strategy of the Company moving away from the exploitation of a portfolio of sports and lifestyle brands to building a business within the in vitro diagnostic devices ("IVD") market place. * A placing to raise circa GBP1 million by way of the issue of 8,398,300 new ordinary shares at a price of 12.75p per share and a commitment to dispose of the existing licensing business. Proposed New Strategy The Board has identified the IVD market place as having significant potential for generating shareholder value and intends to use IBL as a vehicle to build a group focused on the IVD industry, through acquisition. The recent Board appointments bring a wealth of experience in this industry, adding to that of Gordon Hall, and a strong track record of delivering significant returns to the shareholders of companies in which they have been directors. The Board's intention is to deliver attractive returns to shareholders within the next 3-5 years. The target businesses will be within the diagnostics industry, focusing initially on applications which will benefit most from the migration of routine diagnostic testing from the clinical laboratory to the point of care. The target businesses will have a proven product record, significant intellectual property and manufacturing expertise. The IVD Market In the Directors' opinion, there is a substantial opportunity to construct a business that can take advantage of the significant ageing profile of the western world population and help in the diagnosis, treatment and care for older people. In vitro diagnostic medical devices are used for the examination of specimen samples taken from the human body in order to diagnose patients. In particular, IVDs are used in point of care testing and self testing. As more of the routine diagnostic testing moves from the clinical laboratory to the point of care, the Board believes that there will be significant future growth in the use and sale of IVDs. General Meeting Under the AIM Rules for Companies, shareholders' approval is required for the change of strategy and it is proposed to post a circular to shareholders shortly; seeking such approval at a general meeting. Once approved by Shareholders the Company will have 12 months to make an acquisition, or acquisitions, which constitute a reverse acquisition or implement its investing strategy. The Board anticipates it will make an acquisition which will constitute a reverse acquisition within this time frame. Board appointments and changes The three new Directors bring a wealth of experience in the diagnostics industry. David Evans has significant experience and contacts worldwide within the IVD industry and is currently chairman of Immunodiagnostic Systems Holdings plc and Epistem Holdings plc and was formerly a director of BBI Holdings plc ("BBI") and DxS Limited. Julian Baines was until recently Group CEO of BBI where he undertook a management buyout in 2000, a flotation on AIM in 2004 and was responsible for selling the business to IMI Inc in 2007 for circa GBP85 million. Julian has resigned from his executive role at BBI but will remain on the board as a non executive director. Dr Kevin Wilson has been on the board of a number of public and private businesses and was Senior Independent Director of BBI from its AIM flotation to its sale in 2007. Following the new appointments to the Board, Adam Reynolds has become a non-executive director and Tony Hutchinson has stepped down from the Board. The Directors would like to thank Tony for all his efforts over the last 7 years in developing the Admiral brand and assisting in the disposal of trademark registrations. Tony will, in the short term, continue to assist the Board with its strategy of disposing of the licensing business and the Board wishes him well for the future. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
